Vanguard Group Inc Intercept Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$9.99 - $18.71 $26.2 Million - $49.1 Million	-2,622,585 Reduced 55.87%	2,071,232 $38.4 Million
Q2 2023 Aug 14, 2023	BUY	$9.17 - $19.29 $6.95 Million - $14.6 Million	757,898 Added 19.26%	4,693,817 $51.9 Million
Q1 2023 May 15, 2023	BUY	$12.53 - $21.71 $3.73 Million - $6.47 Million	297,984 Added 8.19%	3,935,919 $52.9 Million
Q4 2022 Feb 10, 2023	BUY	$11.61 - $16.11 $10.8 Million - $15 Million	931,521 Added 34.42%	3,637,935 $45 Million
Q3 2022 Nov 14, 2022	BUY	$12.21 - $19.7 $2.41 Million - $3.89 Million	197,255 Added 7.86%	2,706,414 $37.8 Million
Q2 2022 Aug 12, 2022	BUY	$11.23 - $19.59 $1.35 Million - $2.35 Million	119,910 Added 5.02%	2,509,159 $34.7 Million
Q1 2022 May 13, 2022	BUY	$13.37 - $17.79 $5.58 Million - $7.43 Million	417,490 Added 21.17%	2,389,249 $38.9 Million
Q4 2021 Feb 14, 2022	SELL	$14.28 - $19.53 $12.3 Million - $16.8 Million	-858,504 Reduced 30.33%	1,971,759 $32.1 Million
Q3 2021 Nov 12, 2021	SELL	$12.99 - $20.47 $7.05 Million - $11.1 Million	-542,949 Reduced 16.1%	2,830,263 $42 Million
Q2 2021 Aug 13, 2021	BUY	$15.46 - $24.5 $52.1 Million - $82.6 Million	3,373,212 New	3,373,212 $67.4 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.